Literature DB >> 1691160

Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone.

M Brada1, D Dearnaley, A Horwich, H J Bloom.   

Abstract

Between 1986 and 1988 10 patients with primary cerebral lymphoma (PCL) were treated with initial MACOP-B chemotherapy followed by radiotherapy. All demonstrated radiological response to chemotherapy but this did not predict final clinical outcome. The overall median survival was 14 months. Patients with poor MRC neurological performance status (NPS) 2-4 had a median survival of 5 months. Three of 7 patients with NPS 0-1 died and the median survival is 18 months with a median follow-up of 13 months (10-35 months). The results were compared to 25 patients with primary cerebral lymphoma treated between 1963 and 1986 with radiotherapy as the main treatment modality. The overall median survival was 16 months. Patients presenting with poor NPS (2 and 3) had worse survival (median survival 8 months) compared to patients with good NPS (median survival 22 months; p less than 0.025). Patients diagnosed and treated from 1982 to 1986 also had significantly worse prognosis when compared to earlier treated patients. The preliminary results of combined modality therapy are so far not significantly different when compared to historical series and we have to await long-term outcome before recommending combined modality therapy as the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691160     DOI: 10.1016/0360-3016(90)90398-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study.

Authors:  Y Shibamoto; K Sasai; N Oya; M Hiraoka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 2.  Primary central nervous system lymphoma.

Authors:  W S Velasquez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 3.  Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy.

Authors:  L M DeAngelis
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

4.  Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.

Authors:  N Guha-Thakurta; D Damek; C Pollack; F H Hochberg
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 5.  Neurologic sequelae of treatment of primary CNS lymphomas.

Authors:  U Schlegel; H Pels; R Oehring; I Blümcke
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

6.  Primary central nervous system lymphoma: variety of clinical manifestations and survival.

Authors:  D G Kim; D H Nam; H W Jung; K S Choi; D H Han
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

7.  Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.

Authors:  Toshiki Kawamura; Tsuneo Ishiguchi; Yuta Shibamoto; Hiroyuki Ogino; Shunichi Ishihara; Tetsuya Yamada; Kazuhiro Katada; Kazunori Suzuki; Hiromasa Suzuki; Mikio Mimura
Journal:  Radiat Med       Date:  2006-01

8.  Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan.

Authors:  T Hayakawa; K Takakura; H Abe; T Yoshimoto; R Tanaka; K Sugita; H Kikuchi; T Uozumi; T Hori; H Fukui
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Hypophyseal non-Hodgkin's lymphoma presenting with clinical panhypopituitarism successfully treated with chemotherapy.

Authors:  A R Jonkhoff; P C Huijgens; W O Schreuder; G J Teule; J J Heimans
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

10.  Primary central nervous system lymphoma: a role for adjuvant chemotherapy.

Authors:  M C Chamberlain; V A Levin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.